Ruconest conestat alfa ema approval date?

See the DrugPatentWatch profile for Ruconest

When was Ruconest (conestat alfa) approved in the EU?

Ruconest (conestat alfa) received European Medicines Agency (EMA) approval for use in hereditary angioedema (HAE) in 2008. [1]

What does “EMA approval date” usually mean, and where can you find the exact day?

For medicines authorized by the EMA, the “approval date” typically refers to the date of the European Commission authorization based on an EMA opinion (and summaries are often linked to that authorization). The EMA product page and authorization details are the places to confirm the exact day for Ruconest. [2]

What is Ruconest (conestat alfa) used for?

Ruconest (conestat alfa) is used to treat attacks of hereditary angioedema in patients with C1-inhibitor deficiency. [2]

Sources

[1] https://www.ema.europa.eu/en/medicines/human/EPAR/ruconest
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/ruconest/assessment-report